Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 2/2015

01-04-2015 | Research

Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer

Authors: Ottó Dócs, Ferenc Fazakas, Nóra Lugosiné Horváth, László Tóth, Csilla András, Zsolt Horváth, Gábor Méhes

Published in: Pathology & Oncology Research | Issue 2/2015

Login to get access

Abstract

Colorectal cancer (CRC) is a heterogeneous disease presenting with a wide spectrum of morphological and molecular characteristics sometimes even within the same patient. To understand the mechanisms of oscillations in the KRAS status we evaluated the collective of CRC patients tested using allele-specific PCR and Sanger-sequencing. Mutant KRAS allele was observed in 43.3 % of cases. Repeated analysis of KRAS status in recurrent tumors or metastases was performed in 18/665 cases and a total of 6 cases with different KRAS status was found. In three cases the histological pattern of the tumor was identical. In one patient different histology and molecular status was seen between the primary and the recurrent tumor samples. In two further cases localization, histological type and KRAS mutational status all supported the occurrence of synchron/metachron colorectal tumors. In conclusion, both the progression of the original disease but also multiple tumor formation may contribute to mutation status differences during the course of colorectal carcinoma.
Literature
1.
Baselga J (2001) The EGFR as a target for anticancer therapy – focus on cetuximab. Eur J Cancer 37:16–22CrossRef
2.
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319(9):525–532CrossRefPubMed
3.
Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS (2011) Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Gene Chromosom Cancer 50(5):307–312CrossRef
4.
Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R (2004) The COSMIC (catalogue of somatic mutations in cancer) database and website. Br J Cancer 91(2):355–358PubMedCentralPubMed
5.
Tanaka M, Omura K, Watanabe Y, Oda Y, Nakanishi I (1994) Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol 57(1):57–64CrossRefPubMed
6.
Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst 90(9):675–684CrossRefPubMed
7.
Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66(8):3992–3995CrossRefPubMed
8.
Losi L, Baisse B, Bouzourene H, Benhattar J (2005) Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 26(5):916–922CrossRefPubMed
9.
Velho S, Oliveira C, Seruca R (2009) KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases. J Clin Oncol 27(1):158–159, author reply 159CrossRefPubMed
10.
Oltedal S, Aasprong OG, Moller JH, Korner H, Gilje B, Tjensvoll K, Birkemeyer EM, Heikkila R, Smaaland R, Nordgard O (2011) Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy. Int J Color Dis 26(10):1271–1277CrossRef
11.
Knijn N, Mekenkamp LJ, Klomp M, Vink-Borger ME, Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma S, van Krieken JH, Punt CJ, Nagtegaal ID (2011) KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104(6):1020–1026CrossRefPubMedCentralPubMed
12.
Kimura K, Nagasaka T, Hoshizima N, Sasamoto H, Notohara K, Takeda M, Kominami K, Iishii T, Tanaka N, Matsubara N (2007) No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations. J Int Med Res 35(4):450–457CrossRefPubMed
13.
Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, Mauermann O, Izbicki JR, Pantel K, Riethdorf S (2013) Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem 59(1):252–260CrossRefPubMed
14.
Coghlin C, Murray GI (2010) Current and emerging concepts in tumour metastasis. J Pathol 222(1):1–15CrossRefPubMed
15.
Tziris N, Dokmetzioglou J, Giannoulis K, Kesisoglou I, Sapalidis K, Kotidis E, Gambros O (2008) Synchronous and metachronous adenocarcinomas of the large intestine. Hippokratia 12(3):150–152PubMedCentralPubMed
Metadata
Title
Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer
Authors
Ottó Dócs
Ferenc Fazakas
Nóra Lugosiné Horváth
László Tóth
Csilla András
Zsolt Horváth
Gábor Méhes
Publication date
01-04-2015
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-014-9834-2

Other articles of this Issue 2/2015

Pathology & Oncology Research 2/2015 Go to the issue

Research

Tumor Necrosis Factor Alpha (−238 / −308) and TNFRII-VNTR (−322) Polymorphisms as Genetic Biomarkers of Susceptibility to Develop Cervical Cancer Among Tunisians

Research

Apoptotic Effects of Quercitrin on DLD-1 Colon Cancer Cell Line

Research

Prognostic Value of Ki-67 in Breast Carcinoma: Tissue Microarray Method Versus Whole Section Analysis- Potentials and Pitfalls

Research

The Apoptotic Effect of Plant Based Nanosilver in Colon Cancer Cells is a p53 Dependent Process Involving ROS and JNK Cascade

Research

Revealing the Potential Pathogenesis of Glioma by Utilizing a Glioma Associated Protein-Protein Interaction Network

Research

Overexpression of Wild-Type p53-Induced Phosphatase 1 Confers Poor Prognosis of Patients with Nasopharyngeal Carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits